Immunobiological Therapy in Moderate-to-Severe Psoriasis: A Retrospective Cohort Study Investigating the Effects of Inadequate Therapeutic Compliance on Drug Survival - Quiz - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Impact of Noncompliance on Drug Survival in Moderate-to-Severe Psoriasis: A Retrospective Cohort Analysis of Immunobiological Treatments

  • By

  • Luciana A. Ribeiro

  • Patrícia S. Kurizky

  • Rodrigo R. de Sena

  • Samia Fares

  • Gabriel B. F. dos Santos

  • Letícia O. Galvão

  • Licia Maria H. da Mota

  • Ciro M. Gomes

  • July 2, 2026

Share

Original Source(s)

Immunobiological Therapy in Moderate-to-Severe Psoriasis: A Retrospective Cohort Study Investigating the Effects of Inadequate Therapeutic Compliance on Drug Survival

  • by Luciana A. Ribeiro, Patrícia S. Kurizky, Rodrigo R. de Sena, Samia Fares, Gabriel B. F. dos Santos, Letícia O. Galvão, Licia Maria H. da Mota, Ciro M. Gomes

  • July 2, 2026

Related Content

Mental Health May Impact Dermatologic Quality of Life

Poorer dermatology-related quality of life was associated with greater mental health issues, while habitual probiotic intake showed no measurable relationship with these outcomes.

FDA Expands Pediatric Roflumilast Use

The expanded indication is supported by pharmacokinetic, safety, tolerability, exploratory efficacy, and long-term safety data from studies in children aged 2 to 5 years.

FDA Approves Pediatric Risankizumab

Approval expands risankizumab use to pediatric plaque psoriasis and psoriatic arthritis and includes a new 55-mg prefilled syringe for weight-based dosing in patients weighing less than 40 kg.